SCHEMBL13123267

SCHEMBL13123267

CCCCOCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.65
▸ PRSS1 P07477 1/20 0.65
▸ PRSS2 P07478 1/20 0.65
▸ PRSS3 P35030 1/20 0.65
▸ TPSAB1 Q15661 1/20 0.65
▸ TDP1 Q9NUW8 5/20 0.63
▸ HLCS P50747 2/20 0.60
▸ FOLH1 Q04609 2/20 0.59
▸ PKM P14618 3/20 0.59
▸ CNR1 P21554 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ IDE P14735 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ RIN1 Q13671 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ CNR2 P34972 2/20 0.56
▸ PLCD1 P51178 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16478828 0.99 F2 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL14454556 0.96 F2 (0.65) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL16123163 0.95 F2 (0.65) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL17031576 0.95 F2 (0.72) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL17750105 0.95 F2 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL16478814 0.95 F2 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL16478840 0.93 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL10036980 0.93 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL17085557 0.93 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL17750087 0.93 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807619-B2 cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-05 — — US disclosed
US-20090068738-A1 COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068738-A1 COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES PTMS, QPCT, ANPEP F2 2573/4885PRSS1 3042/4885PRSS2 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback